China Animal Husbandry Industry Co Ltd

China Animal Husbandry Industry announced that pentobarbital sodium, jointly applied for by its controlling subsidiary Hubei Zhongmu Anda Pharmaceutical, China Animal Husbandry Group, and Chengdu Animel Biotechnology, has been approved by the Ministry of Agriculture and Rural Affairs as a new veterinary drug in Category III, with a new veterinary drug registration certificate issued and a three-year monitoring period. The product is used for euthanasia of laboratory animals and is an intermediate-acting barbiturate central sedative. The announcement shows that Hubei Zhongmu Anda Pharmaceutical spent 225,800 yuan on research and development for this project.

China Animal Husbandry Industry disclosed that it has completed the core process of a cross-central-enterprise industrial acquisition totaling 727 million yuan through public listing. The company used its own and self-raised funds to acquire a 51 percent stake in Hebei Shengxue Dacheng Pharmaceutical from China Nuclear Uranium, as well as a 72.7272 percent stake in Inner Mongolia Shengxue Dacheng Pharmaceutical from China Nuclear Uranium and other transferors. The transaction has passed the concentration review by the State Administration for Market Regulation, the transaction price has been paid in full, and the property rights transaction contract has officially taken effect. After completion, China Animal Husbandry Industry will directly hold 51 percent of Hebei Shengxue Dacheng, and directly and indirectly hold a combined 86.6363 percent of Inner Mongolia Shengxue Dacheng. The two target companies will become controlling subsidiaries and be included in the consolidated financial statements. The two target companies are mainly engaged in the research, development and production of veterinary drug active pharmaceutical ingredients and preparations, which are highly synergistic with China Animal Husbandry Industry's core animal health business. This transaction is a typical practice of specialized coordination and integration among central enterprises.

China Animal Husbandry Industry announced that, following review by the Ministry of Agriculture and Rural Affairs, its Lanzhou Biological Pharmaceutical Factory has been approved to produce a bivalent inactivated vaccine for swine foot-and-mouth disease types O and South Africa type 1, a bivalent synthetic peptide vaccine for swine foot-and-mouth disease types O and South Africa type 1, and a trivalent inactivated vaccine for cattle and sheep foot-and-mouth disease types O, A, and South Africa type 1, and has obtained the provisional approval documents for veterinary medicinal products.

As of the close on July 15, the horse racing concept sector rose 3.55%, ranking eighth among concept sector gains. Four stocks in the sector advanced, with New Huadu, China Animal Husbandry Industry, and Zhenping leading the gains, up 5.67%, 4.32%, and 2.49% respectively. In terms of capital flows, the sector overall saw a net outflow of 1.28 million yuan from major funds, but New Huadu, China Animal Husbandry Industry, and Zhenping recorded net inflows of 5.66 million yuan, 4.52 million yuan, and 1.51 million yuan respectively, with net inflow ratios of 3.85%, 5.00%, and 1.36%.